Vimarsana
Biggest News Aggregation in the World

Page 3 - Drug Application News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Drug Application. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Drug Application Today - Breaking & Trending Today

Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya™ as Trade Name for TNX-102 SL for the Management of Fibromyalgia - Vimarsana News

Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya™ as Trade Name for TNX-102 SL for the Management of Fibromyalgia

Results from two positive Phase 3 studies point to Tonmya's (TNX-102 SL) potential as a new first-line medicine for chronic use in managing fibromyalgia, a…

Source: biztoc.com
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates - Vimarsana News

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

- $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected for 2023,...

Vera Therapeutics, Inc. Announces Executive Changes - Vimarsana News

Vera Therapeutics, Inc. Announces Executive Changes

Vera Therapeutics, Inc. announced the appointments of two industry veterans to help lead the development of the company?s drug programs including its late-stage product candidate, atacicept, to treat...

Vera Therapeutics Announces Appointment of Industry - Vimarsana News

Vera Therapeutics Announces Appointment of Industry

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and...

FDA Approval of Topical Berdazimer Gel Announced for Molluscum Contagiosum - Vimarsana News

FDA Approval of Topical Berdazimer Gel Announced for Molluscum Contagiosum

The FDA decision on berdazimer gel, 10.3%, represents the second approved treatment for the viral-borne skin disease.